THC|Analyst Targets
THC|Company Info
THC|Insider Trading
THC|Fundamentals
THC|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $5.50 | - | - |
| Q3'26 | $4.67 | $6.64 | +42.3% |
| Q2'26 | $4.26 | $6.12 | +43.5% |
| Q4'25 | $4.09 | $4.70 | +14.8% |
| Q4'24 | $2.83 | $3.44 | +21.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $5.7B | - | - |
| Q3'26 | $5.6B | $5.6B | +1.1% |
| Q2'26 | $5.5B | $5.6B | +2.1% |
| Q4'25 | $5.5B | $5.5B | +0.0% |
| Q4'24 | - | $5.1B | - |
THC|Monthly Returns
Market Data
THC Stock Snapshot
- Market cap
- 21.82B
- P/E ratio
- 9.7
- Day range
- $267.00 – $293.78
- News sentiment
- 59/100 · Neutral
- Analyst target
- $304.14 (+3.7%)
- Consensus
- Buy · 30 analysts
The signal on THC is bullish: price action is confirming the underlying trend, not fighting it. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Reverse DCF
What growth is priced into THC?
At today's price, Tenet Healthcare Corporation needs to grow free cash flow about -1.7% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 7.02% cost of capital. Over the last five years its revenue has trended at 2.6% a year, so the market is asking for 4.3 percentage points below its own delivered rate. On that basis THC looks priced below what its own growth record supports.
- Implied FCF growth
- -1.7%
- Growth trend
- 2.6%
- Growth gap
- -4.3 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 7.02%
- Beta
- 0.76
Behaviour On Record
What THC's own history says about today's numbers
- Realized volatility (21d)
- 23.9% 5th pct
- Below its peak
- -1.1%
- vs 200-day average
- +25.0%
- Up days (1y)
- 49%
Tenet Healthcare Corporation is currently running 23.9% annualised volatility over the last 21 sessions. Measured against THC's own 13 years of daily returns rather than a market-wide average, that is the 5th percentile — unusually subdued by its own history, against a typical reading of 43.2%.
THC is trading -1.1% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -45.0%, and the deepest was -71.7% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +25.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 75th percentile — a somewhat wider gap than its own norm. Over the past year THC closed higher on 49% of sessions, and it is currently 1 session into a rising streak.
On November specifically: over 13 years of records, THC finished the month higher 8 of 13 times, with a median return of +1.9% and an average of +3.2%. Its strongest month historically has been July at +10.9% on average, its weakest September at -6.7%.
Overnight risk is measurable too: THC has opened more than 2% away from the prior close in 288 of 3,268 sessions (8.8% of the time), with the largest gaps running +11.0% and -12.7%.
Across the last 3 dated reports on file, THC moved an average of 2.9% in the session after earnings, closing higher 3 of those 3 times, with a median move of +2.8% and a largest of +4.1%.
All figures computed from 3,269 daily closes between 2013-11-05 and 2026-11-04, split-adjusted, recomputed daily. Percentiles are against THC's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of THC's sector?
Tenet Healthcare Corporation sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #1 of 12
- Sector state
- Leading
- Sector rotation score
- 91
Analyst Consensus Estimates
What do analysts expect THC to earn?
Analysts expect Tenet Healthcare Corporation to earn $22.17 per share in the fiscal year ending Dec 2026 and $22.51 in the fiscal year ending Dec 2028, from 5 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.
Analyst Rating Changes
Are analysts turning bullish or bearish on THC?
Truist Securities most recently reiterated its rating on Tenet Healthcare Corporation to Buy on Nov 3, 2026 with a price target of $305 (from $290). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Truist Securities: Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Earnings Release, Scored
What did Tenet Healthcare Corporation's latest earnings release say?
Most important lines
- 1
Results also include the $147 million favorable net impact described above.
New this quarter - 2
Results also include the net favorable impact of $147 million from transition activities described on page 2.
New this quarter - 3
As a result of this revised timeline, during the three months ended September 30, 2026, we recognized cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million.
New this quarter
Peers & ETF holders
THC peers & ETF holders
Medical Care FacilitiesMarket cap · today
News & sentiment
What is the news saying about THC?
THC rose 13.4% over the month to Nov 4. News tone held between 58 and 79 from Oct 2 to Oct 16, then dropped to 43 on Oct 19.
- Oct 16 -2.9%same day: Tenet Healthcare’s Rally Raises a Key Question About Its Valuation
- Oct 20 +2.2%same day: Tenet Fintech: Turning SME Data Into Business Opportunities With AI
- Nov 4 +10.0%same day: Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
Technical analysis
How strong is THC's momentum right now?
On the daily chart THC ranks at the 71st percentile for momentum against 1,060 stocks and ETFs, a bullish reading.
Institutional ownership
Are big funds buying or selling THC?
82 of the 175 tracked managers added to THC in their latest 13F and 86 trimmed. Together they own 82.2% of the company, worth $11.5B. BlackRock and Boston Partners alone hold 17.6%.
- 1BlackRock, Inc.11.68%$1.6B positionAdded 0.4% last quarter
- 2Boston Partners5.92%$829.1M positionAdded 15.6% last quarter
- $792.9M positionTrimmed 1.8% last quarter
- 4FMR LLC (Fidelity)5.33%$747.3M positionTrimmed 48.6% last quarter
- $728.5M positionTrimmed 0.4% last quarter
- 6State Street Corp3.67%$514.7M positionAdded 1.3% last quarter
- $418.2M positionAdded 46.6% last quarter
- $352.7M positionTrimmed 2.4% last quarter
- 9Citadel Advisors LLC2.36%$330.3M positionAdded 321.6% last quarter
- $319.6M positionAdded 154.3% last quarter
Congressional trading
Is Congress trading THC?
2 members of Congress disclosed 7 THC trades between Jun 11, 2025 and Apr 20, 2026: 3 buys and 4 sells, about $105.0K in estimated value.
What stands out
Click one to highlight its trades in the chartDiscover more
How has THC done against its peers?
Over the six months to Nov 4, THC returned +58.3%. Of the 15 related stocks and ETFs, none did better.
- 1THCThis stockup 58.3%
- 2TMOThermo Fisher Scientific Inc.up 52.9%−5.4 pts
- 3AMGNAmgen Inc.up 49.2%−9.1 pts
- 4LLYEli Lilly and Companyup 47.0%−11.3 pts
- 5DHRDanaher Corporationup 35.3%−22.9 pts
- 6MDTMedtronic plcup 34.4%−23.8 pts
- 7MRKMerck & Co., Inc.up 32.2%−26.1 pts
- 8GILDGilead Sciences, Inc.up 31.9%−26.4 pts
- 16AZNAstrazeneca PLCup 4.0%−54.3 pts